CCB
KERX

Cutter & Co Brokerage’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cutter & Co Brokerage’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$71K – 290
2017
Q3 		$71K Hold
10,000
– – 0.03% 253
2017
Q2 		$72K Hold
10,000
– – 0.03% 261
2017
Q1 		$62K Hold
10,000
– – 0.03% 254
2016
Q4 		$59K Hold
10,000
– – 0.02% 240
2016
Q3 		$53K Buy
+10,000
New +$53.9K 0.02% 236

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cutter & Co Brokerage's KERX Position: Q4 2017 in Review

Cutter & Co Brokerage sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 10,000 shares — an estimated $71K sold.

Cutter & Co Brokerage first reported a position in KERX in Q3 2016 and held it in 5 quarters. The position peaked at $72K in Q2 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Cutter & Co Brokerage reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Cutter & Co Brokerage sold 10,000 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $71K.
  • Cutter & Co Brokerage first reported a position in Keryx Biopharmaceuticals Inc in Q3 2016 and held it in 5 quarters.
  • Cutter & Co Brokerage's Keryx Biopharmaceuticals Inc position peaked at $72K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Cutter & Co Brokerage's 13F filing for Q4 2017, filed 30 Jan 2018.